Recombinant Human Fgr Protein

Product Discontinued

Recombinant Human Fgr Protein Summary

• Description: Recombinant protein for Human Fgr
  
  Source:Baculovirus (Sf9 insect cells)
  Amino Acid Sequence:(P09769)
  
  This product is manufactured by Abcam and distributed by Novus Biologicals. (Abcam Catalog Number: ab60854)
• Source: Sf 9 (baculovirus)
• Protein/Peptide Type: Recombinant Protein
• Gene: FGR
• Purity: >90%, by SDS-PAGE

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • SDS-Page
• Application Notes: Specific activity: 282 nmol phosphate incorporated into Poly(Glu-Tyr) per minute per mg protein at 30C for 15 minutes using a final concentration of 50 uM ATP (0.83 uCi/assay).
• Theoretical MW: 86 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -80C. Avoid freeze-thaw cycles.
• Buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, 25% glycerol
• Concentration: 0.1 mg/ml
• Purity: >90%, by SDS-PAGE

Alternate Names for Recombinant Human Fgr Protein

• c-fgr
• c-src-2 proto-oncogene
• c-src2
• EC 2.7.10
• EC 2.7.10.2
• Fgr
• FLJ43153
• Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog
• MGC75096
• p55-c-fgr protein
• p55c-fgr
• p55-Fgr
• p58c-fgr
• Proto-oncogene c-Fgr
• proto-oncogene tyrosine-protein kinase FGR
• Src2
• SRC2c-fgr protooncogene
• tyrosine-protein kinase Fgr

Background

Fgr is a protooncogene that is a unique member of the tyrosine kinase gene family. It is localized to the distal portion of the short arm of human chromosome 1 at p36.1-36.2 by in situ hybridization (1). Certain lymphomas (but not sarcomas or carcinomas) express fgr-related messenger RNA. This transcript is detected in Burkitt's lymphoma cell lines naturally infected with Epstein-Barr virus (EBV), but not in EBV-negative Burkitt's lymphoma cells (2). Normal umbilical cord or peripheral blood lymphocyte lines established in vitro by EBV infection also contain detectable c-fgr mRNA. Moreover, a 50-fold increase of the steady-state c-fgr mRNA concentration is observed when uninfected Burkitt's lymphoma cell lines are deliberately infected with EBV demonstrating the induction of a proto-oncogene in response to infection by a DNA tumour virus. Fgr expression is limited to normal peripheral blood granulocytes, monocytes, and alveolar macrophages, all of which contain 50 to 100 copies of c-fgr mRNA per cell (3). The c-fgr RNA molecules in these cells consisted of partially spliced transcripts containing intron 7 and completely spliced molecules capable of encoding the predicted p55 c-fgr protein. The level of fgr transcripts begin to increase 2 to 4 h after TPA addition, peak at 8 h, and subsequently declined suggesting transient transcriptional activation of fgr during TPA-induced differentiation. Cycloheximide also causes accumulation of c-fgr transcripts in U937 cells. Thus, c-fgr gene is expressed in a tissue- and development-specific fashion and constitutive expression of c-fgr in U937 cells is regulated by a labile transcriptional repressor.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: FGR